Navigation Links
Study calculates patient time costs associated with cancer care

In 2005, the overall cost of patients' time spent on cancer care was $2.3 billion in the first year after diagnosis, according to a new study in the January 3 issue of the Journal of the National Cancer Institute. The time costs for the 11 cancers studied and for different phases of cancer care varied widely, they write.

Several studies have estimated the direct medical costs of cancer care, but few have attempted to include a patient's time associated with cancer care, such as time spent traveling to and from care, waiting for appointments, and receiving services and treatments, all of which represent time not spent working or pursuing day-to-day activities.

In the new study, Robin Yabroff, Ph.D., of the National Cancer Institute, and colleagues quantified the patient time costs associated with cancer care. They used information from the Surveillance, Epidemiology, and End Results–Medicare database on more than 760,000 patients with 11 different types of cancer and from 1.1 million Medicare enrollees without cancer. Using data from 1995 to 2001, they estimated each patient's time spent at physician and emergency room visits, chemotherapy treatments, radiation therapy, hospitalizations, outpatient surgeries, and imaging procedures. They then estimated how long each patient spent traveling to, waiting for, and receiving care. The net costs were calculated using a dollar value of $15.23 per hour, the median U.S. wage rate in 2002.

During the first 12 months after diagnosis, the average length of time for hospitalization was highest for patients with gastric and ovarian cancers (21.1 and 20.8 days) and shortest for patients with melanoma (2.2 days), prostate cancer (3.8 days) and breast cancer (4.0 days). Compared to similar people without cancer, cancer patients' net time associated with medical care varied, ranging from 17.8 hours for melanoma to 351.3 hours for gastric cancer and 368.1 hours for ovarian cancer. When the researchers
'"/>

Source:Journal of the National Cancer Institute


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study calculates patient time costs associated with cancer care

(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... pleased to announce the 2010 Yeast Genetics and Molecular ... of British Columbia (UBC) in Vancouver, Canada. This ... eukaryotic biology in yeast. Program highlights include presentations ... is also a Member of Parliament. The ...
... discovered a key reason why a form of leukemia ... phase called blast crisis. The study, led by cancer ... G. James Cancer Hospital and Richard J. Solove Research ... when immature white blood cells lose a molecule called ...
... Diego, paleoceanographer Richard Norris is one of 41 scientists presenting ... and myriad other organisms 30 years after the theory was ... paper being released Friday in the journal Science ... the cause of the mass extinction. Norris, contribution to the ...
Cached Biology News:2010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Study identifies key cause of chronic leukemia progression 230 years later, what killed the dinosaurs is revisited 230 years later, what killed the dinosaurs is revisited 3
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... , , CAMBRIDGE, ... ), a biopharmaceutical company engaged in the discovery and development of ... pricing of an underwritten offering of 7,248,936 shares of its common ... and commissions and estimated offering expenses, the company expects to receive ...
... , , SAN DIEGO, Aug. 5 ... will provide partial funds for long-term follow-up testing of patients enrolled ... The funding will enable Ceregene to collect and analyze more ... Parkinson,s disease who were enrolled in the double-blind, controlled trial which ...
... Mass., Aug. 5 NxStage Medical, Inc. (Nasdaq: NXTM ... revenue for the second quarter of 2009 of $36.4 million, an ... for the second quarter of 2008. , , ... in Home, solid machine sales in Critical Care, and continued progress ...
Cached Biology Technology:Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 3Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 4NxStage Reports Second Quarter 2009 Financial Results 2NxStage Reports Second Quarter 2009 Financial Results 3NxStage Reports Second Quarter 2009 Financial Results 4NxStage Reports Second Quarter 2009 Financial Results 5NxStage Reports Second Quarter 2009 Financial Results 6NxStage Reports Second Quarter 2009 Financial Results 7NxStage Reports Second Quarter 2009 Financial Results 8NxStage Reports Second Quarter 2009 Financial Results 9NxStage Reports Second Quarter 2009 Financial Results 10NxStage Reports Second Quarter 2009 Financial Results 11NxStage Reports Second Quarter 2009 Financial Results 12
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Disrupts biological cells for DNA ... 96 well plates (includes 96 well ... consistent lysis across the entire plate ... wells). Can be used for ...
Request Info...
GBL Antibody...
Biology Products: